{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-264707","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.603939+00:00","generated_at":"2026-05-17T00:36:47.656447+00:00","sec_items":["1.01","2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ultragenyx Q3 revenue $160M (+15% YoY); sells 25% Crysvita royalty for $400M","bullets":["Total revenue $160M (+15% YoY); Crysvita $112M, Dojolvi $24M, Evkeeza $17M.","Net loss $180M ($1.81/share) vs $134M ($1.40) in Q3 2024; operating expense $331M.","Received $400M from OMERS for additional 25% Crysvita royalty; repurchase option at $540M.","FY2025 guidance reaffirmed: total rev $640-670M, Crysvita $460-480M, Dojolvi $90-100M.","UX143 OI Phase 3 data expected year-end; DTX401 BLA submission on track for Q4 2025; UX111 BLA resubmission early 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-264707","json":"https://secwatch.observer/filing/0001193125-25-264707.json","markdown":"https://secwatch.observer/filing/0001193125-25-264707.md","text":"https://secwatch.observer/filing/0001193125-25-264707.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000119312525264707/0001193125-25-264707-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000119312525264707/rare-20251103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:36:47.656447+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}